Health, Latest on coronavirus outbreak

Japan approves GSK's antibody treatment for COVID-19 patients

Sotrovimab will be used for COVID-19 patients with mild symptoms, says Japanese Health Ministry

Ahmet Furkan Mercan   | 28.09.2021
Japan approves GSK's antibody treatment for COVID-19 patients

TOKYO

Japan on Monday approved GlaxoSmithKline and and Vir Biotechnology’s Sotrovimab for treatment of patients with mild COVID-19 symptoms.

Japan’s Health Ministry authorized the use of the antibody treatment on the recommendation of a panel of experts.

Sotrovimab, which is administered intravenously, will be used for COVID-19 patients who do not require oxygen supplementation.

Clinical tests showed the drug reduces the risk of hospitalization and death by 79%.​​​​​​​

Anadolu Agency website contains only a portion of the news stories offered to subscribers in the AA News Broadcasting System (HAS), and in summarized form. Please contact us for subscription options.
Related topics
Bu haberi paylaşın